Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Stimulants used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among stimulants are hindered by the absence of direct comparative trials. The goal of this work was to compare the efficacy of methylphenidate and amfetamine formulations through a meta-analysis of double-blind placebo-controlled trials. We analyzed recent published literature on the stimulant therapy of ADHD to describe the variability of drug-placebo effect sizes. A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in children and adolescents published after 1979. Meta-analysis regression assessed the influence of medication type and study design features on medication effects. Twenty-three trials met criteria and were included in this meta-analysis. These trials studied 11 drugs using 19 different outcome measures of hyperactive, inattentive, or impulsive behavior. We found significant differences between amfetamine and methylphenidate products, even after correcting for study design features that might have confounded the results. Our analyses indicate that effect sizes for amfetamine products are significantly, albeit moderately, greater than those for methylphenidate. We found that most measures of effect from all studies were statistically significant. Our findings suggest that amfetamine products may be moderately more efficacious than methylphenidate products, even after controlling for potentially confounding…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meta-analyses have demonstrated that stimulant and non-stimulant medications for ADHD effectively reduce ADHD symptoms inchildren and adults 142,143 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“some patients preferentially respond to and tolerate one or the other 143 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“Although the efficacy of both classes of stimulants is similar”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“It has been speculated that the moderately greater efficacy of AMP-based agents compared with MPH-based agents in ADHD may be related to differences in their molecular actions (33), but to date there is no conclusive clinical evidence to support this speculation.”
In the citing paper
“It is noteworthy that medications for ADHD operate by altering the availability of NE and DA at cortical sites (Faraone and Buitelaar, 2010),”
From Is autonomic nervous system function atypical in Attention Deficit Hyperactivity Disorder (ADHD)? A systematic review of the evidence (2020) · cites this paper as Faraone and Buitelaar, 2010
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Our meta-analysis used the random effects model of DerSimonian and Laird [ 8 ].”
MethodThe meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Methods of Meta-Analysis: Correcting Error and Bias in Research Findings
Schmidt, F. L., & Hunter, J. E. (2015) · doi:10.4135/9781483398105 · Cited by 5,542
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,784
(1967) · Project Euclid (Cornell University) · Cited by 4,720
Research works printed but not linked: 1
- Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104–113
Cited by
Items 201–300 of 485
Rosa, V. D. O., Schmitz, M. D., Maia, C. R. M., Wagner, F., Londero, I., Bassotto, C. D. F., MORITZ, G., de Souza, C. D. S., & Rohde, L. A. (2017) · Trends in Psychiatry and Psychotherapy · doi:10.1590/2237-6089-2016-0039 · Cited by 35
Fried, R. S., DiSalvo, M., Kelberman, C., Adler, A., McCafferty, D., Woodworth, K. Y., Green, A., Biederman, I., Faraone, S. V., & Biederman, J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908014 · Cited by 26
“Although stimulants are safe and effective in treating ADHD (Biederman et al., 2006a; Canadian ADHD Resource Alliance, 2008; Faraone and Buitelaar, 2010; Faraone and Glatt, 2010; Kendall et al., 2008; Kooij et al., 2010; Medori et al., 2008; Spencer et al., 2007, 2013) and help mitigate many of the complications (Barb…”
BackgroundSelf-citationvan Lieshout, M., Luman, M., Schweren, L., Twisk, J. W. R., Faraone, S. V., Heslenfeld, D. J., Hartman, C. A., Hoekstra, P. J., Franke, B., Buitelaar, J. K., et al. (2018) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-018-0449-z · Cited by 30
Self-citationKaczorowski, J. A., Smith, T. F., Shrewsbury, A. M., Thomas, L. R., Knopik, V. S., & Acosta, M. T. (2020) · Behavior Genetics · doi:10.1007/s10519-020-09991-x · Cited by 26
Individualization of Treatments with Drugs Metabolized by CES1: Combining Genetics and Metabolomics
Rasmussen, H. B., Bjerre, D., Línnet, K., Jűrgens, G., Dalhoff, K., Stefánsson, H., Hankemeier, T., Kaddurah‐Daouk, R., Taboureau, O., Brunak, S., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.7 · Cited by 27
Thissen, A. J. A. M., Bralten, J., Rommelse, N. N. J., Vásquez, A. A., Greven, C. U., Heslenfeld, D. J., Luman, M., Oosterlaan, J., Hoekstra, P. J., Hartman, C. A., et al. (2015) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32290 · Cited by 29
“key candidates for ADHD because of the strong therapeutic effects of stimulant medication [Volkow et al., 2002; Faraone and Buitelaar, 2010; Del Campo et al., 2011].”
BackgroundSelf-citationTime Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD
Armstrong, R. B., Damaraju, C., Ascher, S., Schwarzman, L., O’Neill, J., & Starr, H. L. (2012) · Journal of Attention Disorders · doi:10.1177/1087054711425772 · Cited by 23
“…ADHD is robust, ranging from 0.79 to ≥1.0, varying by study design factors, including age range of participant, informant, length of study, dose, comparator, and other factors (Faraone & Buitelaar, 2010; Schachter, Pham, King, Langford, & Moher, 2001; Smith, Waschbusch, Willoughby, & Evans, 2000).”
InfluentialEffectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD
Adler, L. A., Lynch, L. R., Shaw, D. M., Wallace, S. P., O’Donnell, K. E., Ciranni, M. A., Briggie, A. M., & Faraone, S. V. (2017) · Journal of Attention Disorders · doi:10.1177/1087054713485421 · Cited by 23
“Psychostimulant medications are a mainstay of the pharmacologic treatment for children and adults with ADHD (Biederman, Spencer, & Wilens, 2004; Faraone & Buitelaar, 2010) and appear to be more effective than nonstimulant medications (Faraone & Glatt, 2010).”
BackgroundSelf-citationMethylphenidate HCL for the treatment of ADHD in children and adolescents
Childress, A. C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1182986 · Cited by 25
“8.[11] The first longer actingMPHmarketed in the United States was Ritalin-SR® (MPH-SR; Novartis, East Hanover, NJ, USA) sustainedrelease tablets.”
BackgroundRubinson, M., Horowitz, I., Naim‐Feil, J., Gothelf, D., Levit‐Binnun, N., & Moses, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217383 · Cited by 26
Gerlach, M., Banaschewski, T., Coghill, D., Rohde, L. A., & Romanos, M. (2017) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-017-0220-2 · Cited by 27
Jordan, C. J., Taylor, D. M., Dwoskin, L. P., & Kantak, K. M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.017 · Cited by 24
History of attention-deficit hyperactivity disorder (ADHD)
Conners, C. K. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.002 · Cited by 27
Kalucy, D., Nixon, J., Parvizian, M. K., Fernando, P., Sherriff, S., McMellon, J., D’Este, C. A., Eades, S., & Williamson, A. B. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025670 · Cited by 22
“17 22–26 Unfortunately, however, many young people experiencing challenges do not access mental healthcare.”
BackgroundBaseline performance moderates stimulant effects on cognition in youth with ADHD.
Fosco, W. D., Rosch, K. S., Waxmonsky, J. G., Pelham, W. E., & Hawk, L. W. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000374 · Cited by 23
Present and future of developmental neuropsychopharmacology
Arango, C. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.003 · Cited by 23
Geissler, J. M., Jans, T., Banaschewski, T., Becker, K., Renner, T., Brandeis, D., Döpfner, M., Dose, C., Hautmann, C., Holtmann, M. H., et al. (2018) · Trials · doi:10.1186/s13063-018-2635-2 · Cited by 33
Keutayeva, A., Nwachukwu, C. J., Alaran, M., Otarbay, Z., & Abibullaev, B. (2025) · IEEE Access · doi:10.1109/access.2025.3564328 · Cited by 22
“Although stimulant medications demonstrate efficacy, adverse effects such as headaches, sleep disturbances, and decreased appetite frequently occur [149].”
Lee, C., Chen, T., Gao, Q., Hua, C., Song, R., & Huang, X.-P. (2022) · Child Psychiatry & Human Development · doi:10.1007/s10578-022-01361-4 · Cited by 26
“Although par- ent-and teacher-ratings are comparatively more subjective to behavioural tests, both parent and teacher ratings have been considered as valid measures for evaluating clinical efficacy [90].”
BackgroundRamtvedt, B. E., Aabech, H. S., & Sundet, K. S. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0114 · Cited by 23
“Methylphenidate and dextroamphetamine are both highly effective in reducing ADHD symptoms (Arnold 2000; Faraone 2009; Faraone and Buitelaar 2010).”
BackgroundInformant Discrepancies in the Assessment of Attention-Deficit/Hyperactivity Disorder
Kennerley, S., Jaquiery, B., Hatch, B., Healey, M., Wheeler, B. J., & Healey, D. M. (2016) · Journal of Psychoeducational Assessment · doi:10.1177/0734282916670797 · Cited by 26
Kovshoff, H., Banaschewski, T., Buitelaar, J. K., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R., Falissard, B., Gojković, D., Hollis, C. P., et al. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0218 · Cited by 22
“While generally well tolerated (Faraone and Buitelaar 2010), MPH has been associated with a range of adverse events/ reactions over both the short and medium/long term (Cortese et al. 2013).”
BackgroundSelf-citationADHD Medication in the Longer Term
Taylor, E. A. (2019) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000664 · Cited by 28
Döpfner, M., Ose, C., Fischer, R., Ammer, R., & Scherag, A. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0082 · Cited by 23
“Methylphenidate (MPH) is the most frequently used and best studied substance, and the robust effects of immediate release (IR) preparations and modified release preparations (MR) of MPH have been documented in meta-analyses (Banaschewski et al. 2006; Faraone et al. 2006; Faraone and Buitelaar 2010).”
BackgroundChildress, A. C. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0020-1 · Cited by 21
The safety of extended-release drug formulations for the treatment of ADHD
Childress, A. C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1317344 · Cited by 22
Attention deficit disorder/hyperactivity: a scientific overview
Polanczyk, G. V., Casella, E. B., Miguel, E. C., & Reed, U. C. (2012) · Clinics · doi:10.6061/clinics/2012(10)01 · Cited by 22
“9 for adults for the reduction of ADHD symptoms (14,15).”
Pride, N. A., Barton, B., Hutchins, P., Coghill, D., Korgaonkar, M. S., Hearps, S. J. C., Rouel, M., Malarbi, S., North, K. N., & Payne, J. M. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021800 · Cited by 21
“0).(38) 39 fMRI studies in ADHD participants indicate that acute doses of MPH upregulate and normalise under functioning brain regions in ADHD, including the basal ganglia and prefrontal cortex.”
Hayley, A. C., Shiferaw, B. A., & Downey, L. A. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101929 · Cited by 21
Childress, A. C., Hoo-Cardiel, A., & Lang, P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1706480 · Cited by 20
“The stimulants have proven efficacy [12].”
A Cautionary Note on Extended Kaplan–Meier Curves for Time-varying Covariates
Sjölander, A. (2020) · Epidemiology · doi:10.1097/ede.0000000000001188 · Cited by 18
Martínez-Raga, J., Knecht, C., & de Alvaro, R. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s65735 · Cited by 25
“Indeed, the treatment ESs across the different studies are comparable with that observed with other medications used for treating children and adolescents with ADHD.(23,71) Moreover, GXR may show greater symptom reduction than ATX.”
InfluentialHegvik, T., Jacobsen, K. K., Fredriksen, M., Zayats, T., & Haavik, J. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1540-7 · Cited by 20
“been shown superior to placebo in providing symptom relief in ADHD (Epstein et al. 2014; Faraone and Buitelaar 2010), and is believed to exert its effect by inhibiting the dopamine transporter (encoded by DAT/SLC6A3 gene) and/ or the noradrenaline transporter (encoded by NET/SLC6A2 gene) (Engert and Pruessner 2008).”
BackgroundTowards an Evidence-based Taxonomy of Nonpharmacologic Treatments for ADHD
Faraone, S. V., & Antshel, K. M. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.06.003 · Cited by 16
Self-citationWeisler, R., Childress, A., Adler, L., Kollins, S., Goodman, D., Hamdani, & Dirks, B. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s47087 · Cited by 16
“25,26 Response to stimulant therapy is robust in both children 27 and adults.”
Ekıncı, O., Direk, M. Ç., Güneş, S., Teke, H., Ekinci, N., Yıldırım, F., & Okuyaz, Ç. (2016) · Brain and Development · doi:10.1016/j.braindev.2016.11.005 · Cited by 16
Connor, D. F. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0143-3 · Cited by 18
“Evidence exists for the efficacy of stimulants [40, 41], both amphetamine and methylphenidate preparations [42], atomoxetine [43, 44], and alpha2-adrenergic agonists [45– 47] in pediatric ADHD treatment.”
BackgroundFridman, M., Hodgkins, P. S., Kahle, J. S., & Erder, M. H. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.001 · Cited by 16
“We utilized a meta-regression analysis similar to previously conducted analyses of ADHD stimulant and non-stimulant medication efficacy [13,16].”
MethodDavidson, F., Rusak, B., Chambers, C. T., & Corkum, P. V. (2018) · Canadian Journal of School Psychology · doi:10.1177/0829573518770593 · Cited by 22
Muris, P., Roodenrijs, D., Kelgtermans, L., Sliwinski, S., Berlage, U., Baillieux, H., Deckers, A., Gunther, M., Paanakker, B., & Holterman, I. (2018) · Child Psychiatry & Human Development · doi:10.1007/s10578-018-0812-x · Cited by 24
“Placebo-controlled research has clearly demonstrated that that this type of medication is effective: in about 70% of the children and adolescents the intensity of the prototypical symptoms of the disorder is substantially reduced [11], a treatment effect that is associated with a large effect size of around 1 [12].”
BackgroundSeok, J., Vaughan, B. S., Lew, B. J., Ahmad, A., Blair, J., & Hwang, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-33979-2 · Cited by 20
ADHD matures: time for practitioners to do the same?
Bolea-Alamanac, B. M., Adamou, M., Arif, M., Asherson, P. J., Gudjonsson, G. H., Müller, U., Nutt, D. J., Pitts, M. E., Thome, J., & Young, S. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111410898 · Cited by 19
Skokauskas, N., McNicholas, F., Masaud, T., & Frodl, T. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834776bd · Cited by 21
Ziv‐Baran, T., Zacay, G., Modan‐Moses, D., Reingold, S. M., Mekori‐Domachevsky, E., & Levy‐Shraga, Y. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04929-x · Cited by 18
“Meta-analyses have shown the efficacy of stimulants for treating ADHD in children and adults [7, 8].”
BackgroundA Comment on Sherlin, Arns, Lubar, and Sokhadze, 2010
Lofthouse, N., Arnold, L. E., & Hurt, E. A. (2010) · Journal of Neurotherapy · doi:10.1080/10874208.2010.523340 · Cited by 13
Interventions for Attention-Deficit Hyperactivity Disorder: A Year in Review
Johnston, C., & Park, J. L. (2015) · Current Developmental Disorders Reports · doi:10.1007/s40474-014-0034-2 · Cited by 18
Motamedi, S., Sheibani, V., Rajizadeh, M. A., Esmaeilpour, K., & Sepehri, G. (2019) · Toxin Reviews · doi:10.1080/15569543.2019.1633544 · Cited by 15
Lilja, M. M., Sandblom, E., Lichtenstein, P., Serlachius, E., Hellner, C., Bhagia, J., & Halldner, L. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09424-2 · Cited by 14
New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development
Heal, D. J., Gosden, J., & Smith, S. L. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_332 · Cited by 17
Is there a place for dietetic interventions in adult ADHD?
Breda, V., Cerqueira, R. O., Ceolin, G., Koning, E., Fabe, J., McDonald, A., Gomes, F. A., & Brietzke, E. M. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110613 · Cited by 25
Stimulants, cognition and ADHD
Baroni, A., & Castellanos, F. X. (2015) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2015.04.010 · Cited by 14
“Introduction For more than 50 years, psychostimulants have been considered prototypical cognitive enhancers [1] and have been used as first-line pharmacologic treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) with overwhelming evidence of their short-term efficacy for the behavioral and subjective symptom…”
BackgroundThe Ecology of ADHD in the Schools
Rogers, M., Boggia, J., Ogg, J. A., & Volpe, R. (2015) · Current Developmental Disorders Reports · doi:10.1007/s40474-015-0038-6 · Cited by 22
Shaw, P. (2016) · JAMA · doi:10.1001/jama.2016.3427 · Cited by 13
Biederman, J., DiSalvo, M., Green, A., Woodworth, K. Y., Law, C., Gabrieli, J. D. E., & Faraone, S. V. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001374 · Cited by 14
Self-citationChildress, A. C. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.001 · Cited by 16
Management of Psychotropic Medication Side Effects in Children and Adolescents
García, G., Logan, G. E., & Gonzalez–Heydrich, J. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.012 · Cited by 18
Cook, A. A., Johnson, C. M., & Bradley‐Johnson, S. (2015) · Child & Family Behavior Therapy · doi:10.1080/07317107.2015.1000234 · Cited by 17
“E-mail: cook2ar@cmich.edu Child & Family Behavior Therapy, 37:38–50, 2015 Copyright # Taylor & Francis Group, LLC ISSN: 0731-7107 print=1545-228X online DOI: 10.1080/07317107.2015.1000234 38 hyperactivity (Faraone & Buitelaar, 2010), several shortcomings are apparent.”
InfluentialFaraone, S. V., & Zhang‐James, Y. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32155 · Cited by 14
“We included five drugs approved by the US Food and Drug Administration for the treatment of ADHD (methylphenidate, amphetamine, guanfacine, atomoxetine, and clonidine), each having substantial data indicating efficacy for ADHD [Faraone and Buitelaar, 2010; Faraone and Glatt, 2010].”
MethodSelf-citationReliability and Validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised
Faraone, S. V., Childress, A. C., Wigal, S. B., Kollins, S. H., McDonnell, M. A., DeSousa, N. J., & Sallee, F. R. (2015) · Journal of Attention Disorders · doi:10.1177/1087054715619009 · Cited by 14
“…Murphy, & Fischer, 2010; Biederman, Mick, & Faraone, 2000), and although treatment studies have documented the efficacy of ADHD medications (Faraone & Buitelaar, 2010; Faraone & Glatt, 2010), long-term studies suggest that some symptoms and impairments persist with treatment (Fredriksen et…”
BackgroundSelf-citationPharmacotherapy in Psychiatric Disorders of Children: Current Evidence and Trends
Kölch, M. G., & Plener, P. L. (2016) · Pharmacopsychiatry · doi:10.1055/s-0042-117644 · Cited by 13
SKILLS – A psychoeducational group programme for children with ADHD
Lantz, S., Fornwall, C., Lööf, M., & Isaksson, J. (2021) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12727 · Cited by 14
Rates of switching stimulants in consecutively referred medication naïve adults with ADHD
Biederman, J., DiSalvo, M., Green, A., Woodworth, K. Y., Gilfix, T., Law, C., Gabrieli, J. D. E., & Faraone, S. V. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13370 · Cited by 14
Self-citationJoshi, G., & Wilens, T. E. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.012 · Cited by 13
Hogue, A., Bobek, M., Tau, G. Z., & LEVIN, F. R. (2014) · Child & Family Behavior Therapy · doi:10.1080/07317107.2014.967631 · Cited by 15
Spencer, T. J., Bhide, P. G., Zhu, J., Faraone, S. V., Fitzgerald, M., Yule, A. M., Uchida, M., Spencer, A. E., Hall, A. M., Koster, A. J., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11012 · Cited by 16
Self-citationWernicke, J., Zabel, J. T., Zhang, Y., Becker, B., & Montag, C. (2020) · Early Human Development · doi:10.1016/j.earlhumdev.2019.104943 · Cited by 13
Dehnavi, A. Z., Elmitwalli, I., Alsharif, H., Razavi, A. S., Gumpel, T., Smith, A. A., Weinstock, R. S., Faraone, S. V., & Zhang‐James, Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111566 · Cited by 16
Self-citationWu, F., Zhang, W., Ji, W., Zhang, Y., Jiang, F., Li, G., Hu, Y., Wei, X., Wang, S.-Y., Wang, S.-Y., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01831-4 · Cited by 16
Weerkamp, P. M. M., Geuens, S., Collin, P., Goemans, N., Vermeulen, R. J., Waele, L. D., Hendriksen, J. G. M., & Klinkenberg, S. (2023) · Neuromuscular Disorders · doi:10.1016/j.nmd.2023.05.011 · Cited by 15
“Methylphenidate has been proven to be effective in numerous studies and meta-analyses in many different populations [25-27], but treatment can also be compromised by a range of adverse effects like elevated blood pressure and heart rate, restlessness, sleep difficulties, reduced appetite and weight loss, headaches and…”
Hogue, A., Bobek, M., & Evans, S. W. (2014) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2014.07.002 · Cited by 18
“Medication is Not (Usually) Sufficient to Address School Problems for Adolescents with ADHD Stimulant medication is recommended by many as the first-line treatment option for ADHD in adolescents (Faraone & Buitelaar, 2010).”
BackgroundAntel, J., Albayrak, Ö., Heusch, G., Banaschewski, T., & Hebebrand, J. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0522-8 · Cited by 11
Drug therapy in ADHD in people with intellectual disabilities
Courtenay, K., & Elstner, S. (2016) · Advances in Mental Health and Intellectual Disabilities · doi:10.1108/amhid-06-2015-0032 · Cited by 13
Nasser, A. F., Kosheleff, A. R., Hull, J. T., Liranso, T., Qin, P., Busse, G. D., Fava, M., Maletic, V., Rubin, J. S., & López, F. A. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14330 · Cited by 13
Ramtvedt, B. E., & Sundet, K. S. (2014) · The Clinical Neuropsychologist · doi:10.1080/13854046.2014.960453 · Cited by 12
A Reply to Lofthouse, Arnold, and Hurt (2010)
Sherlin, L. H., Arns, M., Lubar, J. F., & Sokhadze, E. (2010) · Journal of Neurotherapy · doi:10.1080/10874208.2010.523350 · Cited by 10
Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice
Sifeddine, W., Ba-M’hamed, S., Landry, M., & Bennis, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00459-3 · Cited by 12
“They facilitate the release and the action of various neurotransmitters including dopamine and noradrenaline and exhibit robust clinical efficacy [1, 7].”
BackgroundBatsis, M., Dagalakis, U., Stratakis, C. A., Prodanov, T., Papadakis, G. Z., Adams, K. T., Lodish, M. B., & Pacák, K. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-106725 · Cited by 10
Brydges, C. R., Ozolnieks, K. L., & Roberts, G. (2018) · Journal of Attention Disorders · doi:10.1177/1087054718772143 · Cited by 12
“This is supported by current pharmacotherapy approaches in treating ADHD, which involves the use of psychostimulants such as methylphenidate and dexamphetamine that target the dopaminergic and noradrenergic systems (Faraone & Buitelaar, 2010).”
MethodGesser‐Edelsburg, A., & Boukai, R. H. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2120-9 · Cited by 9
Yang, K.-H., Lane, H., Chang, Y., & Tzang, R. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab034 · Cited by 17
Pozanicline for the treatment of attention-deficit/hyperactivity disorder
Childress, A. C., & Sallee, F. R. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.956078 · Cited by 10
“Non-stimulant drugs approved for the treatment of ADHD include the selective norepinephrine reuptake inhibitor atomoxetine (ATX) and the central alpha2A-adrenergic receptor agonists guanfacine extended-release (GXR) and clonidine extended-release (CLON-XR).”
BackgroundInfluentialVance, A. L. A., Winther, J., & Rennie, K. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2010.01941.x · Cited by 14
EEG neurofeedback for executive functions in children with neurodevelopmental challenges
Landes, J. K., Reid, C. L., Arns, M., Badcock, N. A., Ros, T., Enriquez‐Geppert, S., Bulsara, M. K., Brini, S., Rabipour, S., Mason, M., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012890 · Cited by 12
Öğütlü, H., Mertoğlu, C., Gök, G., & Neşelioğlu, S. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113546 · Cited by 8
The Pharmaceutical Economics of Child Psychiatric Drug Treatment
Schlander, M. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791959917 · Cited by 9
Weed, E. D. (2016) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217416636561 · Cited by 12
“7.(6,17,21) In general, stimulant medications are considered equally efficacious, but there is some data to support that amphetamine-based stimulants have a slightly greater effect size thanmethylphendate(17) and that lisdexamfetamine may have improved response compared to methylphenidate osmotic controlledrelease (OR…”
BackgroundModerators and Other Predictors of Methylphenidate Response in Children and Adolescents with ADHD
D’Aiello, B., Vara, S. D., Rossi, P. D., Pretelli, I., Vicari, S., & Menghini, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031640 · Cited by 11
“Studies have demonstrates that patients with ADHD improve significantly in EF when on methylphenidate (MPH), the first-choice treatment for ADHD in the developmental age [9,10].”
BackgroundScassellati, C., & Bonvicini, C. (2015) · InTech eBooks · doi:10.5772/60860 · Cited by 12
“They have virtually identical clinical effects, although AMP formulations are modestly more efficacious than MPH [19].”
BackgroundFrölich, J., Banaschewski, T., Spanagel, R., Döpfner, M., & Lehmkuhl, G. (2012) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000185 · Cited by 10
Gendy, M. N. S., Ibrahim, C., Sloan, M. E., & Foll, B. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_253 · Cited by 10
Fazel, M. S. (2015) · BMJ · doi:10.1136/bmj.h5875 · Cited by 11
Training of Awareness in ADHD: Leveraging Metacognition
Lenartowicz, A., DeSchepper, B. G., & Simpson, G. V. (2024) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20240006 · Cited by 16
“Medications (including stimulants and non-stimulants) have a high-reported efficacy in reducing symptoms [11,12].”
BackgroundNeuropsychiatric Symptoms After Brain Tumor Resection in Children and Adolescents: A Scoping Review
Keng, A., Stewart, D. E., & Sheehan, K. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2021.06.007 · Cited by 8
Najib, J. (2012) · Adolescent Health, Medicine and Therapeutics · doi:10.2147/ahmt.s19815 · Cited by 8
“8) with methylphenidate for each positive outcome for total ADHD symptoms.(32) The meta-analysis also noted that the largest effect size was similar to that observed in Biederman et al’s Phase III trial(29) and the apparent superiority of LDX may be that it reflects greater efficacy of amphetamine compared to nonamphe…”
BackgroundResultEmpirical Evidence on the Value of Pharmaceuticals
Garthwaite, C., & Duggan, M. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780199742998.013.0015 · Cited by 10
“While few studies directly compared the efficacy of different stimulants, Faraone and Buitelaar (2009) reported results from a meta-analysis that showed the amphetamine based products are superior to methylphenidate across a variety of outcomes.”
Nooripour, R., Hosseinian, S., Afrouz, G. A., & Bakhshani, N. (2018) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.82012 · Cited by 12
“In this regard, neurofeedback, which is considered as a possibly effective intervention to decrease ADHD symptoms in ADHD and autism spectrum disorders, might as well be able to improve neurocognitive functions (24).”
BackgroundZhang‐James, Y., Lloyd, D. R., James, M. L., Yang, L., Richards, J. B., & Faraone, S. V. (2019) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20190021 · Cited by 8
Self-citationGüvenmez, O., Çubuk, M. Ö., & Güneş, S. (2020) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.15586/jptcp.v27i2.665 · Cited by 8
Hüsser, A. M., Fourdain, S., & Gallagher, A. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64148-9.00017-x · Cited by 10
Määttä, J. I., van den Bosch, R., Papadopetraki, D., Hofmans, L., Lambregts, B., Westbrook, A., Verkes, R., & Cools, R. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/d3h8e · Cited by 10
“In line with the observation that methylphenidate can decrease symptoms of inattention and hyperactivity (Faraone & Buitelaar, 2010), it has been shown to enhance behavioral and cognitive control (Li et al., 2010; Linssen, Vuurman, Sambeth, & Riedel, 2012; Moeller et al., 2012; Nandam et al.,…”
Metadata
- Authors
- Faraone, S. V., & Buitelaar, J.
- Affiliations
- SUNY Upstate Medical University (US)
- Radboud University Nijmegen (NL)
- Corresponding author
- Faraone, Stephen V.
- Venue
- European Child & Adolescent Psychiatry
- Published
- 2009-09-10
- Volume
- 19
- Issue
- 4
- Pages
- 353-364
- ISSN
- 1018-8827 (ISSN-L)
- 1435-165X
- OpenAlex
- W2099805984
- Cited by
- 485
- References
- 54
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 14 · 2023: 20 · 2022: 22 · 2021: 21 · 2020: 35 · 2019: 36 · 2018: 29 · 2017: 31 · 2016: 42 · 2015: 53 · 2014: 47 · 2013: 40 · 2012: 26
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- attention deficit hyperactivity disorder, stimulant medication, methylphenidate, amphetamine, drug efficacy comparison, placebo effect, hyperactivity, inattention, impulsivity, children and adolescents, dopamine signaling
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Humans, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.